Global Granulomatosis with Polyangiitis Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Granulomatosis with Polyangiitis Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Granulomatosis with Polyangiitis Drug by Country/Region, 2017, 2022 & 2028

2.2 Granulomatosis with Polyangiitis Drug Segment by Type

2.2.1 Benralizumab

2.2.2 Avacopan

2.2.3 Rituximab Biosimilar

2.2.4 Others

2.3 Granulomatosis with Polyangiitis Drug Sales by Type

2.3.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Granulomatosis with Polyangiitis Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Type (2017-2022)

2.4 Granulomatosis with Polyangiitis Drug Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Granulomatosis with Polyangiitis Drug Sales by Application

2.5.1 Global Granulomatosis with Polyangiitis Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Granulomatosis with Polyangiitis Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Application (2017-2022)

3 Global Granulomatosis with Polyangiitis Drug by Company

3.1 Global Granulomatosis with Polyangiitis Drug Breakdown Data by Company

3.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Company (2020-2022)

3.1.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2020-2022)

3.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Company (2020-2022)

3.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2020-2022)

3.3 Global Granulomatosis with Polyangiitis Drug Sale Price by Company

3.4 Key Manufacturers Granulomatosis with Polyangiitis Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Granulomatosis with Polyangiitis Drug Product Location Distribution

3.4.2 Players Granulomatosis with Polyangiitis Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Granulomatosis with Polyangiitis Drug by Geographic Region

4.1 World Historic Granulomatosis with Polyangiitis Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Geographic Region

4.2 World Historic Granulomatosis with Polyangiitis Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Granulomatosis with Polyangiitis Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue by Country/Region

4.3 Americas Granulomatosis with Polyangiitis Drug Sales Growth

4.4 APAC Granulomatosis with Polyangiitis Drug Sales Growth

4.5 Europe Granulomatosis with Polyangiitis Drug Sales Growth

4.6 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Growth

5 Americas

5.1 Americas Granulomatosis with Polyangiitis Drug Sales by Country

5.1.1 Americas Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022)

5.1.2 Americas Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022)

5.2 Americas Granulomatosis with Polyangiitis Drug Sales by Type

5.3 Americas Granulomatosis with Polyangiitis Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Granulomatosis with Polyangiitis Drug Sales by Region

6.1.1 APAC Granulomatosis with Polyangiitis Drug Sales by Region (2017-2022)

6.1.2 APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2022)

6.2 APAC Granulomatosis with Polyangiitis Drug Sales by Type

6.3 APAC Granulomatosis with Polyangiitis Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Granulomatosis with Polyangiitis Drug by Country

7.1.1 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022)

7.1.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022)

7.2 Europe Granulomatosis with Polyangiitis Drug Sales by Type

7.3 Europe Granulomatosis with Polyangiitis Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Granulomatosis with Polyangiitis Drug by Country

8.1.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type

8.3 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug

10.3 Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug

10.4 Industry Chain Structure of Granulomatosis with Polyangiitis Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Granulomatosis with Polyangiitis Drug Distributors

11.3 Granulomatosis with Polyangiitis Drug Customer

12 World Forecast Review for Granulomatosis with Polyangiitis Drug by Geographic Region

12.1 Global Granulomatosis with Polyangiitis Drug Market Size Forecast by Region

12.1.1 Global Granulomatosis with Polyangiitis Drug Forecast by Region (2023-2028)

12.1.2 Global Granulomatosis with Polyangiitis Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Granulomatosis with Polyangiitis Drug Forecast by Type

12.7 Global Granulomatosis with Polyangiitis Drug Forecast by Application

13 Key Players Analysis

13.1 Bionovis SA

13.1.1 Bionovis SA Company Information

13.1.2 Bionovis SA Granulomatosis with Polyangiitis Drug Product Offered

13.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Bionovis SA Main Business Overview

13.1.5 Bionovis SA Latest Developments

13.2 Bristol-Myers Squibb Company

13.2.1 Bristol-Myers Squibb Company Company Information

13.2.2 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Offered

13.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Bristol-Myers Squibb Company Main Business Overview

13.2.5 Bristol-Myers Squibb Company Latest Developments

13.3 ChemoCentryx Inc

13.3.1 ChemoCentryx Inc Company Information

13.3.2 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Offered

13.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 ChemoCentryx Inc Main Business Overview

13.3.5 ChemoCentryx Inc Latest Developments

13.4 Coherus BioSciences Inc

13.4.1 Coherus BioSciences Inc Company Information

13.4.2 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Offered

13.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Coherus BioSciences Inc Main Business Overview

13.4.5 Coherus BioSciences Inc Latest Developments

13.5 Genor BioPharma Co Ltd

13.5.1 Genor BioPharma Co Ltd Company Information

13.5.2 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Offered

13.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Genor BioPharma Co Ltd Main Business Overview

13.5.5 Genor BioPharma Co Ltd Latest Developments

13.6 GlaxoSmithKline Plc

13.6.1 GlaxoSmithKline Plc Company Information

13.6.2 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Offered

13.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 GlaxoSmithKline Plc Main Business Overview

13.6.5 GlaxoSmithKline Plc Latest Developments

13.7 Iltoo Pharma

13.7.1 Iltoo Pharma Company Information

13.7.2 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Offered

13.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Iltoo Pharma Main Business Overview

13.7.5 Iltoo Pharma Latest Developments

13.8 Panacea Biotec Ltd

13.8.1 Panacea Biotec Ltd Company Information

13.8.2 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Offered

13.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Panacea Biotec Ltd Main Business Overview

13.8.5 Panacea Biotec Ltd Latest Developments

13.9 Sandoz International GmbH

13.9.1 Sandoz International GmbH Company Information

13.9.2 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Offered

13.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Sandoz International GmbH Main Business Overview

13.9.5 Sandoz International GmbH Latest Developments

13.10 The International Biotechnology Center (IBC) Generium

13.10.1 The International Biotechnology Center (IBC) Generium Company Information

13.10.2 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Offered

13.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 The International Biotechnology Center (IBC) Generium Main Business Overview

13.10.5 The International Biotechnology Center (IBC) Generium Latest Developments

14 Research Findings and Conclusion

Table 1. Granulomatosis with Polyangiitis Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Granulomatosis with Polyangiitis Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Benralizumab

Table 4. Major Players of Avacopan

Table 5. Major Players of Rituximab Biosimilar

Table 6. Major Players of Others

Table 7. Global Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 8. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2022)

Table 9. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2022) & ($ million)

Table 10. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2022)

Table 11. Global Granulomatosis with Polyangiitis Drug Sale Price by Type (2017-2022) & (USD/Pcs)

Table 12. Global Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 13. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2022)

Table 14. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2022)

Table 15. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2022)

Table 16. Global Granulomatosis with Polyangiitis Drug Sale Price by Application (2017-2022) & (USD/Pcs)

Table 17. Global Granulomatosis with Polyangiitis Drug Sales by Company (2020-2022) & (K Pcs)

Table 18. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Company (2020-2022)

Table 19. Global Granulomatosis with Polyangiitis Drug Revenue by Company (2020-2022) ($ Millions)

Table 20. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2020-2022)

Table 21. Global Granulomatosis with Polyangiitis Drug Sale Price by Company (2020-2022) & (USD/Pcs)

Table 22. Key Manufacturers Granulomatosis with Polyangiitis Drug Producing Area Distribution and Sales Area

Table 23. Players Granulomatosis with Polyangiitis Drug Products Offered

Table 24. Granulomatosis with Polyangiitis Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Granulomatosis with Polyangiitis Drug Sales by Geographic Region (2017-2022) & (K Pcs)

Table 28. Global Granulomatosis with Polyangiitis Drug Sales Market Share Geographic Region (2017-2022)

Table 29. Global Granulomatosis with Polyangiitis Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 30. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Geographic Region (2017-2022)

Table 31. Global Granulomatosis with Polyangiitis Drug Sales by Country/Region (2017-2022) & (K Pcs)

Table 32. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Country/Region (2017-2022)

Table 33. Global Granulomatosis with Polyangiitis Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 34. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Country/Region (2017-2022)

Table 35. Americas Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)

Table 36. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2017-2022)

Table 37. Americas Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 38. Americas Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2017-2022)

Table 39. Americas Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 40. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2022)

Table 41. Americas Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 42. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2022)

Table 43. APAC Granulomatosis with Polyangiitis Drug Sales by Region (2017-2022) & (K Pcs)

Table 44. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2017-2022)

Table 45. APAC Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2022) & ($ Millions)

Table 46. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2017-2022)

Table 47. APAC Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 48. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2022)

Table 49. APAC Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 50. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2022)

Table 51. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)

Table 52. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2017-2022)

Table 53. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 54. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2017-2022)

Table 55. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 56. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2022)

Table 57. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 58. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2022)

Table 59. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)

Table 60. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2017-2022)

Table 61. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 62. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2017-2022)

Table 63. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 64. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2022)

Table 65. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2022)

Table 67. Key Market Drivers & Growth Opportunities of Granulomatosis with Polyangiitis Drug

Table 68. Key Market Challenges & Risks of Granulomatosis with Polyangiitis Drug

Table 69. Key Industry Trends of Granulomatosis with Polyangiitis Drug

Table 70. Granulomatosis with Polyangiitis Drug Raw Material

Table 71. Key Suppliers of Raw Materials

Table 72. Granulomatosis with Polyangiitis Drug Distributors List

Table 73. Granulomatosis with Polyangiitis Drug Customer List

Table 74. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 75. Global Granulomatosis with Polyangiitis Drug Sales Market Forecast by Region

Table 76. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 77. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Region (2023-2028)

Table 78. Americas Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 79. Americas Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 80. APAC Granulomatosis with Polyangiitis Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 81. APAC Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 82. Europe Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 83. Europe Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 84. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 85. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Type (2023-2028) & (K Pcs)

Table 87. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Type (2023-2028)

Table 88. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 89. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Type (2023-2028)

Table 90. Global Granulomatosis with Polyangiitis Drug Sales Forecast by Application (2023-2028) & (K Pcs)

Table 91. Global Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Application (2023-2028)

Table 92. Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 93. Global Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Application (2023-2028)

Table 94. Bionovis SA Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 95. Bionovis SA Granulomatosis with Polyangiitis Drug Product Offered

Table 96. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 97. Bionovis SA Main Business

Table 98. Bionovis SA Latest Developments

Table 99. Bristol-Myers Squibb Company Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 100. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Offered

Table 101. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 102. Bristol-Myers Squibb Company Main Business

Table 103. Bristol-Myers Squibb Company Latest Developments

Table 104. ChemoCentryx Inc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 105. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Offered

Table 106. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 107. ChemoCentryx Inc Main Business

Table 108. ChemoCentryx Inc Latest Developments

Table 109. Coherus BioSciences Inc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 110. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Offered

Table 111. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 112. Coherus BioSciences Inc Main Business

Table 113. Coherus BioSciences Inc Latest Developments

Table 114. Genor BioPharma Co Ltd Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 115. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Offered

Table 116. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 117. Genor BioPharma Co Ltd Main Business

Table 118. Genor BioPharma Co Ltd Latest Developments

Table 119. GlaxoSmithKline Plc Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 120. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Offered

Table 121. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 122. GlaxoSmithKline Plc Main Business

Table 123. GlaxoSmithKline Plc Latest Developments

Table 124. Iltoo Pharma Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 125. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Offered

Table 126. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 127. Iltoo Pharma Main Business

Table 128. Iltoo Pharma Latest Developments

Table 129. Panacea Biotec Ltd Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 130. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Offered

Table 131. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 132. Panacea Biotec Ltd Main Business

Table 133. Panacea Biotec Ltd Latest Developments

Table 134. Sandoz International GmbH Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 135. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Offered

Table 136. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 137. Sandoz International GmbH Main Business

Table 138. Sandoz International GmbH Latest Developments

Table 139. The International Biotechnology Center (IBC) Generium Basic Information, Granulomatosis with Polyangiitis Drug Manufacturing Base, Sales Area and Its Competitors

Table 140. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Offered

Table 141. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 142. The International Biotechnology Center (IBC) Generium Main Business

Table 143. The International Biotechnology Center (IBC) Generium Latest Developments

List of Figures

Figure 1. Picture of Granulomatosis with Polyangiitis Drug

Figure 2. Granulomatosis with Polyangiitis Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Granulomatosis with Polyangiitis Drug Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Granulomatosis with Polyangiitis Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Granulomatosis with Polyangiitis Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Benralizumab

Figure 10. Product Picture of Avacopan

Figure 11. Product Picture of Rituximab Biosimilar

Figure 12. Product Picture of Others

Figure 13. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2021

Figure 14. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2022)

Figure 15. Granulomatosis with Polyangiitis Drug Consumed in Hospital

Figure 16. Global Granulomatosis with Polyangiitis Drug Market: Hospital (2017-2022) & (K Pcs)

Figure 17. Granulomatosis with Polyangiitis Drug Consumed in Clinic

Figure 18. Global Granulomatosis with Polyangiitis Drug Market: Clinic (2017-2022) & (K Pcs)

Figure 19. Granulomatosis with Polyangiitis Drug Consumed in Others

Figure 20. Global Granulomatosis with Polyangiitis Drug Market: Others (2017-2022) & (K Pcs)

Figure 21. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2022)

Figure 22. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application in 2021

Figure 23. Granulomatosis with Polyangiitis Drug Revenue Market by Company in 2021 ($ Million)

Figure 24. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company in 2021

Figure 25. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Geographic Region (2017-2022)

Figure 26. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Geographic Region in 2021

Figure 27. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2017-2022)

Figure 28. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Country/Region in 2021

Figure 29. Americas Granulomatosis with Polyangiitis Drug Sales 2017-2022 (K Pcs)

Figure 30. Americas Granulomatosis with Polyangiitis Drug Revenue 2017-2022 ($ Millions)

Figure 31. APAC Granulomatosis with Polyangiitis Drug Sales 2017-2022 (K Pcs)

Figure 32. APAC Granulomatosis with Polyangiitis Drug Revenue 2017-2022 ($ Millions)

Figure 33. Europe Granulomatosis with Polyangiitis Drug Sales 2017-2022 (K Pcs)

Figure 34. Europe Granulomatosis with Polyangiitis Drug Revenue 2017-2022 ($ Millions)

Figure 35. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales 2017-2022 (K Pcs)

Figure 36. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue 2017-2022 ($ Millions)

Figure 37. Americas Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2021

Figure 38. Americas Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2021

Figure 39. United States Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 40. Canada Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 41. Mexico Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 42. Brazil Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. APAC Granulomatosis with Polyangiitis Drug Sales Market Share by Region in 2021

Figure 44. APAC Granulomatosis with Polyangiitis Drug Revenue Market Share by Regions in 2021

Figure 45. China Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 46. Japan Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 47. South Korea Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. India Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Australia Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2021

Figure 52. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2021

Figure 53. Germany Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 54. France Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 55. UK Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. Italy Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. Russia Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country in 2021

Figure 59. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country in 2021

Figure 60. Egypt Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 61. South Africa Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 62. Israel Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. Turkey Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. GCC Country Granulomatosis with Polyangiitis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug in 2021

Figure 66. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug

Figure 67. Industry Chain Structure of Granulomatosis with Polyangiitis Drug

Figure 68. Channels of Distribution

Figure 69. Distributors Profiles